Two months after Travere Therapeutics, Inc.’s Filspari (sparsentan) cleared the US Food and Drug Administration for treatment of immunoglobulin A nephropathy (IgAN), the company stumbled on its way to a second indication for the dual endothelin receptor antagonist. But even though the Phase III DUPLEX clinical trial of sparsentan in focal segmental glomerulosclerosis (FSGS) failed, Travere and its partner CSL Vifor plan to speak with US and EU regulators about potential paths to approval in FSGS.
Travere closed down 30.8% at $15.65 on 2 May based on the DUPLEX trial results, which the companies disclosed after the market closed on 1 May. CSL Vifor is responsible...